← Leaderboards
Glen Gaughan
Sujana Biotech, Llc
$805,184
Attributed
$805,184
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $383.9K · FY2017–19$500K$375K$250K$125K$0
'17
'18
'19
Funding mix
By agency
NIH$805,184 · 1
By mechanism
N01$805,184 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Aortic Aneurysm”
- Magali Noval Rivas · Cedars-Sinai Medical Center$5,021,319
- Gregory Andrew Roth · University Of Washington$3,181,247
- Ajay Houde · Annoviant, Inc$3,028,801
- Francesca Seta · Boston University Medical Campus$2,979,770
- Kenneth W. Mahaffey · Stanford University$2,629,431
- Bradley Graham Leshnower · Emory University$2,211,662
Research focus
Aortic AneurysmAreaBiologyBiotechnologyCoronary ArteriosclerosisDissectionFoundationsInflammationInsightInterestIntracranial ArteryLinkLymphatic DiseasesLymphatic SystemMolecularMonoclonal AntibodiesPeripheral Arterial DiseasePharmaceutical PreparationsProduct DevelopmentProgramsPulmonary HypertensionPulmonary Vascular DisorderSafetyThrombosis
Grant awards (3)
IGF::OT::IGF VITA 2 - DEVELOPING AN ANTI-THROMBOTIC MONOCLONAL ANTIBODY (MAB) WITH IMPROVED SAFETY AND EFFICACY$195,294
N01 · FY2019 · HL · contact PI
DEVELOPING AN ANTI-THROMBOTIC MONOCLONAL ANTIBODY (MAB) WITH IMPROVED SAFETY AND EFFICACY, VITA 2$226,023
N01 · FY2018 · HL · contact PI
IGF::OT::IGF VITA 2 - DEVELOPING AN ANTI-THROMBOTIC MONOCLONAL ANTIBODY (MAB) WITH IMPROVED SAFETY AND EFFICACY$383,867
N01 · FY2017 · HL · contact PI